DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Roche - 1 tiragolumab - 1 Morgan - 1 Roche's - 1 TIGIT - 1 Paul Arnold - 1 Christy Santhosh - 1 Jason Neely - 1
Top related locs:
U.S Zurich Bengaluru
Top related orgs:
Merck & Co - 1 Gilead Sciences - 1 iTeos Therapeutics - 1 Arcus Biosciences - 1 Thomson - 1

Search resuls for: "tiragolumab"


2 mentions found


☆ Roche inadvertently publishes positive interim trial data on lung cancer drug
  + stars: | 2023-08-23 | by ( Ludwig Burger Rachel More | Ludwig Burger | Rachel More | ) www.reuters.com   time to read: +2 min
BERLIN, Aug 23 (Reuters) - Roche (ROG.S) inadvertently published positive lung cancer drug trial data from an interim analysis, boosting the Swiss drug maker's shares even though more data will be needed to confirm the treatment's efficacy. Roche said on Wednesday that market participants had made it aware of the inadvertent disclosure of an interim data analysis on new immunotherapy tiragolumab, part of an experimental class of drugs known as anti-TIGIT. The data lifted Roche shares by 5% and sent shares of other companies testing anti-TIGIT drugs higher. J.P. Morgan analysts said the interim data suggested a survival benefit was within reach in the final analysis, but the clinical relevance remained uncertain. The unintended disclosure regards the second interim analysis of a Phase III trial known as Skyscraper 1.
Persons: Roche, tiragolumab, Morgan, Roche's, TIGIT, Paul Arnold, Christy Santhosh, Jason Neely, Friederike Heine, Mark Potter Organizations: Merck & Co, Gilead Sciences, iTeos Therapeutics, Arcus Biosciences, Thomson Locations: U.S, Zurich, Bengaluru
☆ Roche's Alzheimer's drug fails to meet goal in long awaited trial
  + stars: | 2022-11-14 | by ( Ludwig Burger | ) www.reuters.com   time to read: +4 min
Nov 14 (Reuters) - Roche said (ROG.S) its Alzheimer's drug candidate could not clearly be shown to slow dementia progression in two drug trials, failing to draw level with a recent development success by rivals Biogen (BIIB.O) and Eisai (4523.T). Within each study, volunteers were randomly assigned to receive either the injectable antibody drug gantenerumab or a placebo. The quest to develop an Alzheimer's drug, targeting beta-amyloid or other molecules, has been beset by a long list of study failures. But rival Biogen in September scored a surprise trial success with an experimental Alzheimer's drug that it developed with Eisai, rebuilding confidence among industry executives and researchers in the beta-amyloid approach. Schwan earlier this year sought to curb expectations for the Graduate trials but the head of Roche's pharma unit last month acknowledged that Biogen's success with lecanemab had reignited hopes.
0 next >>
Total: 2